2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Date Issued
2019-03-26
Author(s)
Huang, Wei-Chun
Hsu, Chih-Hsin
Sung, Shih-Hsien
WEN-JENG HSUEH
Chu, Chun-Yuan
Chang, Chih-Ping
Chiu, Yu-Wei
Wu, Chun-Hsien
Chang, Wei-Ting
Lin, Shoa-Lin
Cheng, Chin-Chang
YI-JU WU
Wu, Shu-Hao
Hsieh, Tsu-Yi
Fu, Morgan
Dai, Zen-Kong
Cheng, Shu-Meng
TSOC pulmonary hypertension committee
Abstract
Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH.4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.
Subjects
Guideline; Pulmonary arterial hypertension; Pulmonary hypertension
SDGs
Other Subjects
ambrisentan; anticoagulant agent; beraprost; bosentan; calcium channel blocking agent; diuretic agent; endothelin receptor antagonist; guanylate cyclase activator; iloprost; macitentan; phosphodiesterase V inhibitor; prostacyclin; prostacyclin derivative; prostanoid; riociguat; selexipag; sildenafil; tadalafil; treprostinil; algorithm; Article; blood vessel reactivity; chronic thromboembolic pulmonary hypertension; clinical evaluation; combination drug therapy; congenital heart disease; connective tissue disease; Eisenmenger complex; follow up; heart right ventricle failure; human; lung vascular resistance; oxygen therapy; percutaneous transluminal angioplasty; practice guideline; prognostic assessment; pulmonary hypertension; pulmonary veno-occlusive disease; randomized controlled trial (topic); risk assessment; risk factor; screening; systemic lupus erythematosus; systemic sclerosis; Taiwan; transthoracic echocardiography; tricuspid valve regurgitation; venous thromboembolism; cardiology; medical society; pulmonary hypertension; Cardiology; Humans; Practice Guidelines as Topic; Pulmonary Arterial Hypertension; Societies, Medical; Taiwan
Type
journal article